We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Heart Aging Protein Found

By Biotechdaily staff writers
Posted on 12 Nov 2007
Cardiovascular researchers working with a mouse model of the aging heart have identified a specific protein that contributes to deterioration of heart function and which may be a target for drug treatment to prevent or reverse the effects of aging on the heart muscle.

Investigators at the University of Alberta (Canada) focused on the protein CD36. CD36 is an integral membrane protein found on the surface of many cell types in vertebrate animals and is also known as FAT, SCARB3, GP88, glycoprotein IV (gpIV), and glycoprotein IIIb (gpIIIb). CD36 is a member of the class B scavenger receptor family of cell surface proteins. It binds many ligands including collagen, thrombospondin, erythrocytes parasitized with Plasmodium falciparum, oxidized low-density lipoprotein, native lipoproteins, oxidized phospholipids, and long-chain fatty acids. Recent work using genetically modified rodents have identified a clear role for CD36 in fatty acid and glucose metabolism, heart disease, taste, and dietary fat processing in the intestine.

In the current study published in the November 6, 2007, issue of Circulation, investigators genetically engineered a line of mice lacking CD36. When compared to normal mice, it was seen that the hearts of the CD36-deficient animals had lower levels of intramyocardial lipids, demonstrated improved mitochondria-derived ATP production, had significantly enhanced function, and had a blunted hypertrophic response.

The authors concluded that, "These findings provide evidence that CD36 mediates an age-induced cardiomyopathy in mice and suggest that inhibition of CD36 may be an approach for the treatment of the detrimental age-related effects on cardiac performance.”


Related Links:
University of Alberta

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Drug Testing Assays
Atellica DT 250 Analyzer
Immunofluorescence Analyzer
IFA System

Latest BioResearch News

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
12 Nov 2007  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
12 Nov 2007  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
12 Nov 2007  |   BioResearch